Aneja Nikhil 4

What Happened
Nikhil Aneja, Principal Accounting Officer of Aligos Therapeutics (ALGS), received a derivative grant of 9,450 shares on March 9, 2026. The grant shows an acquisition price of $0.00 (i.e., no cash paid). This is a company award (not a market purchase or sale) and does not represent an immediate sale or cash transaction.

Key Details

• Transaction date: March 9, 2026; Filing date: March 11, 2026 (filed within the typical 2-business-day Form 4 window).
• Grant: 9,450 shares; reported price: $0.00; total reported value: $0.00 (derivative award).
• Vesting/Exercise: Per footnote, 1/48th of the shares vest monthly starting March 9, 2026; fully vested and exercisable on the fourth anniversary, subject to continued service.
• Shares owned after transaction: Not specified in the provided filing details.
• Footnote of record: F1 describes the 48-month monthly vesting schedule (service condition applies).

Context
This is a grant/award of a derivative security that vests over four years — a common form of employee compensation intended to retain personnel. It is neither a buy nor a sell in the open market and does not by itself indicate the insider is altering their immediate exposure to the stock.